These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 38453435

  • 1. Tolerability, safety and efficacy of a novel phosphate binder VS-505 (AP301): a Phase 2 dose-escalation and dose-ranging study in patients undergoing maintenance hemodialysis.
    Zhuang B, Gan L, Liu B, Yuan W, Shi M, Peng A, Wang L, Chen X, Liu T, Zhang S, Wang S, Gao Q, Wang B, Zheng H, Liu C, Luo Y, Ye H, Lin H, Li Y, He Q, Zheng F, Luo P, Long G, Lu W, Li K, Yang J, Liu YC, Zhang Z, Li X, Zhang W, Zuo L.
    Nephrol Dial Transplant; 2024 Sep 27; 39(10):1649-1661. PubMed ID: 38453435
    [Abstract] [Full Text] [Related]

  • 2. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM, PA21 Study Group.
    Kidney Int; 2014 Sep 27; 86(3):638-47. PubMed ID: 24646861
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J.
    Nephron; 2020 Sep 27; 144(9):428-439. PubMed ID: 32585670
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL, Plosker GL.
    Drugs; 2015 Apr 27; 75(5):533-42. PubMed ID: 25761962
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T, Origasa H, Kameoka C, Kaneko Y, Kanoh H.
    Ther Apher Dial; 2014 Jun 27; 18 Suppl 2():24-32. PubMed ID: 24975892
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.
    Fathallah-Shaykh S, Drozdz D, Flynn J, Jenkins R, Wesseling-Perry K, Swartz SJ, Wong C, Accomando B, Cox GF, Warady BA.
    Pediatr Nephrol; 2018 Feb 27; 33(2):325-333. PubMed ID: 28900759
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM, Sucroferric Oxyhydroxide Study Group.
    Nephrol Dial Transplant; 2015 Jun 27; 30(6):1037-46. PubMed ID: 25691681
    [Abstract] [Full Text] [Related]

  • 15. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.
    Nephrol Dial Transplant; 2014 Jan 27; 29(1):152-60. PubMed ID: 24151017
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group.
    Am J Kidney Dis; 2013 May 27; 61(5):759-66. PubMed ID: 23369827
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.
    Nephrol Dial Transplant; 2019 Jul 01; 34(7):1163-1170. PubMed ID: 29846719
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M, Kasuga H, Joseph D, Sawata H, Junge G, Moore A, Akiba T.
    Clin Exp Nephrol; 2014 Feb 01; 18(1):135-43. PubMed ID: 23670305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.